Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer
← catalyst calendarNCT07480356 · readout ≤ 619 d
Sponsored by Protara Therapeutics (industry) · TARA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
284estimated
Sites
6
Countries
Ukraine, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-29 | actual | When the study began enrolling |
| Primary completion | Apr 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2026-03-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Bladder (Urothelial, Transitional Cell) Cancer
- Non-Muscle Invasive Bladder Carcinoma
- Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Interventions
- Drug: TARA-002
- Drug: Investigator's Choice of Intravesical Chemotherapy
Primary outcome
what the primary-completion date above is the date OFIncidence of high-grade complete response
measured Month 6
Permalink · TARA's whole pipeline · Catalyst calendar · Every registered study · What changed